SCHEMBL7635367

SCHEMBL7635367

CCCCCCCCCCCCOCCOCCOC(C)=O

nearest known ligand 0.61

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
TSHR P16473 3/20 0.59
CES2 O00748 2/20 0.59
MEN1 O00255 1/20 0.57
THRB P10828 1/20 0.57
HTT P42858 1/20 0.57
KMT2A Q03164 1/20 0.57
MAPT P10636 1/20 0.57
NAAA Q02083 1/20 0.50
DGKA P23743 1/20 0.50
EPHX1 P07099 1/20 0.47
FAAH O00519 2/20 0.46
PLA2G2C Q5R387 1/20 0.45
HCAR2 Q8TDS4 1/20 0.43
RAD52 P43351 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7706869 1.00 ALDH1A1 (0.61) ALDH1A1TSHRCES2MEN1THRB
SCHEMBL599581 1.00 ALDH1A1 (0.61) ALDH1A1TSHRCES2MEN1THRB
SCHEMBL599481 1.00 ALDH1A1 (0.61) ALDH1A1TSHRCES2MEN1THRB
SCHEMBL22408893 1.00 ALDH1A1 (0.61) ALDH1A1TSHRCES2MEN1THRB
SCHEMBL22408899 1.00 ALDH1A1 (0.61) ALDH1A1TSHRCES2MEN1THRB
SCHEMBL19064977 1.00 ALDH1A1 (0.61) ALDH1A1TSHRCES2MEN1THRB
SCHEMBL11171482 1.00 ALDH1A1 (0.61) ALDH1A1TSHRCES2MEN1THRB
SCHEMBL536992 1.00 ALDH1A1 (0.61) ALDH1A1TSHRCES2MEN1THRB
SCHEMBL22444981 1.00 ALDH1A1 (0.61) ALDH1A1TSHRCES2MEN1THRB
SCHEMBL28098968 1.00 ALDH1A1 (0.61) ALDH1A1TSHRCES2MEN1THRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260041663-A1 PREVENTION OF ROSACEA INFLAMMATION UNIV CALIFORNIA (US) 2026-02-12 US claimed
US-12285404-B2 Prevention of rosacea inflammation THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-04-29 US claimed
US-20230181518-A1 PREVENTION OF ROSACEA INFLAMMATION THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2023-06-15 US claimed
US-11382890-B2 Prevention of rosacea inflammation THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2022-07-12 US claimed
EP-0934078-B1 PERMEATION ENHANCERS FOR TRANSDERMAL DRUG DELIVERY COMPOSITIONS, DEVICES, AND METHODS ALZA CORP (US) 2002-12-18 EP claimed
US-6004578-A FOR ENHANCING THE PERCUTANEOUS ABSORPTION OF DRUGS WHEN ADMINISTERED TO A BODY SURFACE OR MEMBRANE ALZA CORPORATION (US) 1999-12-21 US claimed
EP-0934078-A2 PERMEATION ENHANCERS FOR TRANSDERMAL DRUG DELIVERY COMPOSITIONS, DEVICES, AND METHODS ALZA CORPORATION (US) 1999-08-11 EP claimed
WO-1998017315-A2 PERMEATION ENHANCERS FOR TRANSDERMAL DRUG DELIVERY COMPOSITIONS, DEVICES, AND METHODS ALZA CORPORATION (US) 1998-04-30 WO claimed
US-20260083685-A1 METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2026-03-26 US disclosed
US-20260060913-A1 BIOACTIVE WALNUT PEPTIDES FOR TREATING HAIR LOSS L'OREAL (FR) 2026-03-05 US disclosed
US-20260041663-A1 PREVENTION OF ROSACEA INFLAMMATION UNIV CALIFORNIA (US) 2026-02-12 US disclosed
US-12514828-B2 Methods of permeabilizing the blood brain barrier UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2026-01-06 US disclosed
US-20250213646-A1 BIOACTIVE WALNUT PEPTIDES AND COMPOSITIONS FOR TREATING SKIN L'OREAL (FR) 2025-07-03 US disclosed
US-20250186472-A1 COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS Neonc Technologies, Inc. 2025-06-12 US disclosed
WO-2022082093-A1 COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS Neonc Technologies, Inc. (US) 2022-04-21 WO disclosed
WO-2022082218-A1 IMPROVED DERMATOLOGICAL COMPOSITIONS AND USES THEREOF BABAPOUR REZA (US) 2022-04-21 WO disclosed
EP-0934078-B1 PERMEATION ENHANCERS FOR TRANSDERMAL DRUG DELIVERY COMPOSITIONS, DEVICES, AND METHODS ALZA CORP (US) 2002-12-18 EP disclosed
US-6004578-A FOR ENHANCING THE PERCUTANEOUS ABSORPTION OF DRUGS WHEN ADMINISTERED TO A BODY SURFACE OR MEMBRANE ALZA CORPORATION (US) 1999-12-21 US disclosed
EP-0934078-A2 PERMEATION ENHANCERS FOR TRANSDERMAL DRUG DELIVERY COMPOSITIONS, DEVICES, AND METHODS ALZA CORPORATION (US) 1999-08-11 EP disclosed
WO-1998017315-A2 PERMEATION ENHANCERS FOR TRANSDERMAL DRUG DELIVERY COMPOSITIONS, DEVICES, AND METHODS ALZA CORPORATION (US) 1998-04-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250186472-A1 COMBINATION OF POH AND REMDESIVIR FOR TREATMENT OF CNS INFECTIONS CFH, AQP4, MAG ALDH1A1 2939/4885TSHR 4486/4885CES2 345/4885
US-20260083685-A1 METHODS OF PERMEABILIZING THE BLOOD BRAIN BARRIER CD4, EPCAM, ICOS ALDH1A1 1230/4885TSHR 219/4885CES2 323/4885
US-20260060913-A1 BIOACTIVE WALNUT PEPTIDES FOR TREATING HAIR LOSS TYR, CUTA, ARGLU1 ALDH1A1 4486/4885TSHR 1854/4885CES2 2591/4885
US-20260041663-A1 PREVENTION OF ROSACEA INFLAMMATION CPA3, CTSD, TPSD1 ALDH1A1 2072/4885TSHR 2866/4885CES2 479/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.